Table 1.
Thyroid Tumors Analyzed for hTERT Alternative Splice Variant Patterns by Subtype
| |
Malignant (n = 60) |
Benign (n = 73) |
||||||
|---|---|---|---|---|---|---|---|---|
| Final histology | PTC (n = 28) | FVPTC (n = 24) | FC (n = 5) | HC (n = 3) | FA (n = 21) | AN (n = 31) | HA (n = 12) | LcT (n = 9) |
| hTERT positive (n = 114) | 28 | 21 | 3 | 1 | 21 | 25 | 6 | 9 |
| hTERT full-length >0.33a (n = 41) | 24 (86%) | 4 (19%) | 3 (100%) | 1 (100%) | 1 (5%) | 1 (4%) | 4 (67%) | 3 (33%) |
a
An hTERT full-length expression cut point of 0.33 corresponded to a specificity of 0.85 and a sensitivity of 0.60.
hTERT, human telomerase reverse transcriptase; AN, adenomatoid nodule; FA, follicular adenoma; FC, follicular carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; HA, Hürthle cell adenoma; HC, Hürthle cell carcinoma; LcT, lymphocytic thyroiditis nodule; PTC, papillary thyroid carcinoma.